The new medication, which is now undergoing preclinical studies, is aimed at limiting the formation of advanced glycation end products (AGEs)
FOR IMMEDIATE RELEASE
Ekaterinburg, Russia -- Scientists of Ural Federal University (Ekaterinburg, Russia) have won an open competition by the Ministry of Education and Science of the Russian Federation for the development of medicine for diabetes mellitus treatment. At the moment, the state contract is passing the signing process.
The project named "Preclinical Studies of a Medication Effecting Advanced Glycation end Products (AGEs) and Receptors (RAGE) for the Prevention and Treatment of Complications of Diabetes Mellitus" is being implemented within the frames of the Federal Target Program "Development of the pharmaceutical and medical industry of the Russian Federation for the period up to 2020 and further prospects."
Associate Professor of the Department of Organic and Biomolecular Chemistry, Institute of Chemical Engineering UrFU, Mikhail Varaksin notes that currently the pharmacotherapy of diabetes is associated with normalization of blood glucose levels, although the most important etiopathogenetic factor in the development of late complications is the formation of advanced glycation end products in the process of the Maillard's reaction, non-enzymatic glycosylation (glycation) of proteins.
‘Nowadays, there is no medication with a similar mechanism of pharmacological action that is allowed for clinical use,’ says Mikhail Varaksin. ‘Therefore, the development of medication limiting the formation of advanced glycation end products (AGEs) on long-lived proteins, collagen in particular, interfering with their interaction with specific receptors for AGE (RAGE), as a result, blocking the main pathogenetic pathways of late complications development (diabetic nephropathy, neuropathy, cardiomyopathy) is an extremely urgent task of social and economic significance.’
The work on the project involves preclinical studies of the medication effecting advanced glycation end products of collagen and receptors for the prevention and treatment of complications of diabetes mellitus.
The total financing of the project will reach 44 million rubles, of which 33 million rubles will be allocated from the federal budget. The remaining 11 million rubles will be extrabudgetary co-financed. The period of the contract is 2017-2019. The co-executor of the project is Volgograd State Medical University.
Nowadays, diabetes takes a special place among a number of socially significant diseases related to chronic pandemics; it shows rapid prevalence. The total number of patients with diabetes in the Russian Federation at the end of 2016 was 4.348 million people (2.97% of the population).